Zhang et al., by integrating somatic mutation data and clinical information from 631 melanoma samples, discovered that FAT1 mutations in this tumor type could also predict better immunotherapy responses, simultaneously associating with an activated immune microenvironment and immune signaling pathways (Zhang et al., 2022). This evidence concerns the gene FAT1 and melanoma.